<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421626</url>
  </required_header>
  <id_info>
    <org_study_id>231</org_study_id>
    <nct_id>NCT03421626</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)</brief_title>
  <official_title>Clinical Evaluation of the Xpert BCR-ABL Ultra Assay on the GeneXpert Instrument Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cepheid</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cepheid</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the performance of an assay that detects mRNA
      transcript levels in patients diagnosed with CML. The study is conducted at locations within
      the United States. Testing is performed on peripheral blood specimens provided by eligible
      enrolled patients. Results from this study will not be used for patient management decisions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">April 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Method comparison to an on-market molecular diagnostic assay</measure>
    <time_frame>Baseline = testing upon enrollment</time_frame>
    <description>Comparison of Xpert to an on-market test for the quantitation of BCR-ABL</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Leukemia, Myelogenous, Chronic</condition>
  <arm_group>
    <arm_group_label>Primary Enrollment</arm_group_label>
    <description>Initial enrollment of patients with history of CML</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xpert BCR-ABL Ultra</intervention_name>
    <description>Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML</description>
    <arm_group_label>Primary Enrollment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females at least 18 years of age who were previously diagnosed with CML from
        primary care clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prospective specimens:

               -  Patient is at least 18 years of age

               -  Patient has provided documented informed consent as required by the reviewing
                  IRB. Experimental Bill of Rights will also be documented for all subjects
                  enrolled in applicable states.

               -  Patient has been diagnosed with CML.

               -  Patient consents to provide at least 12 mL of peripheral blood for study purposes

          -  frozen specimens:

               -  Specimen is from a subject diagnosed with CML

               -  Specimen meets the manufacturer's criteria to support testing by both diagnostic
                  assays

        Exclusion Criteria:

          -  prospective specimens:

               -  Patient is considered to be of insufficient health to supply the required volume
                  of peripheral blood by his/her health care provider

               -  Patient has been previously enrolled

          -  frozen specimens: â€¢ Specimen previously enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Brown</last_name>
    <phone>847-228-3298</phone>
    <email>sarah.brown@cepheid.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Broward Oncology Associates</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Patierno</last_name>
      <phone>954-771-0692</phone>
      <email>barrerasl@mindspring.com</email>
    </contact>
    <investigator>
      <last_name>Luis Barreras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Bittner</last_name>
      <phone>208-367-7954</phone>
      <email>Olga.Bittner@saintalphonsus.org</email>
    </contact>
    <investigator>
      <last_name>Alan Langerak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WJB Dorn VA Medical Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Mason</last_name>
      <phone>803-776-4000</phone>
      <phone_ext>5347</phone_ext>
      <email>kathryn.Mason3@va.gov</email>
    </contact>
    <investigator>
      <last_name>Mohammed Wallam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnn Lorenzo</last_name>
      <phone>206-667-7252</phone>
      <email>jmlorenz@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Vivian Oehler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital Center</name>
      <address>
        <city>Bridgeport</city>
        <state>West Virginia</state>
        <zip>26330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Shaw</last_name>
      <phone>304-293-6251</phone>
      <email>yshaw@wvctn.org</email>
    </contact>
    <investigator>
      <last_name>Salman Osman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Shaw</last_name>
      <phone>304-293-6251</phone>
      <email>yshaw@wvctn.org</email>
    </contact>
    <investigator>
      <last_name>Arvinder Bir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue Jahnke</last_name>
      <phone>715-221-6278</phone>
      <email>jahnke.susan@marshfieldclinic.org</email>
    </contact>
    <investigator>
      <last_name>Kajal Sitwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

